[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI: 10.3322/caac.21660.
[2] de Matteis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study[J]. Cancer, 2002, 94(4):895-901. DOI: 10.1002/cncr.20335.abs.
[3] Fisusi FA, Akala EO. Drug combinations in breast cancer therapy[J]. Pharm Nanotechnol, 2019, 7(1):3-23. DOI: 10.2174/2211738507666190122111224.
[4] Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women[J]. Curr Treat Options Oncol, 2019, 20(12):86. DOI: 10.1007/s11864-019- 0685-7.
[5] Izumikawa T, Uyama T, Okuura Y, et al. Involvement of chondroitin sulfate synthase-3 (chondroitin synthase-2) in chondroitin polymerization through its interaction with chondroitin synthase-1 or chondroitin-polymerizing factor[J]. Biochem J, 2007, 403(3):545-552. DOI: 10.1042/BJ20061876.
[6] Hwang S, Mahadevan S, Qadir F, et al. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas[J]. Cancer, 2013, 119(24):4249-4258. DOI: 10.1002/cncr.28354.
[7] Hou XM, Zhang T, Da Z, et al. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway[J]. Pathol Res Pract, 2019, 215(5):988-994. DOI: 10.1016/j.prp.2019.02.005.
[8] Hou XM, Baloch Z, Zheng ZH, et al. Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer[J]. Cancer Manag Res, 2019, 11:3275-3283. DOI: 10.2147/CMAR.S192036.
[9] Kalathas D, Triantaphyllidou IE, Mastronikolis NS, et al. The chondroitin/dermatan sulfate synthesizing and modifying enzymes in laryngeal cancer: expressional and epigenetic studies[J]. Head Neck Oncol, 2010, 2:27. DOI: 10.1186/1758-3284-2-27.
[10] Duan X, Yang J, Jiang B, et al. Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration[J]. Cell Cycle, 2021, 20(5-6):591-602. DOI: 10.1080/15384101.2021. 1890951.
[11] Little PJ, Ballinger ML, Burch ML, et al. Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process[J]. Open Biochem J, 2008, 2:135-142. DOI: 10.2174/1874091X00802010135.
[12] Kitagawa H, Izumikawa T, Uyama T, et al. Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization[J]. J Biol Chem, 2003, 278(26):23666-23671. DOI: 10.1074/jbc.M302493200.
[13] Siebert JR, Conta Steencken A, Osterhout DJ. Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair[J]. Biomed Res Int, 2014, 2014:845323. DOI: 10.1155/2014/845323.
[14] Mizumoto S, Yamada S. An overview of in vivo functions of chondroitin sulfate and dermatan sulfate revealed by their deficient mice[J]. Front Cell Dev Biol, 2021, 9:764781. DOI: 10.3389/fcell.2021.764781.
[15] Nakagawa N, Izumikawa T, Kitagawa H, et al. Sulfation of glucuronic acid in the linkage tetrasaccharide by HNK-1 sulfotransferase is an inhibitory signal for the expression of a chondroitin sulfate chain on thrombomodulin[J]. Biochem Biophys Res Commun, 2011, 415(1):109-113. DOI: 10.1016/j.bbrc.2011.10.023.
[16] Mizumoto S, Yamada S, Sugahara K. Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins[J]. Curr Opin Struct Biol, 2015, 34:35-42. DOI: 10.1016/j.sbi.2015.06.004.
[17] Park SB, Hwang KT, Chung CK, et al. Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer[J]. Clin Exp Metastasis, 2020, 37(6):657-674. DOI: 10.1007/s10585-020-10060-0.
[18] Winship A, Van Sinderen M, Heffernan-Marks A, et al. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration[J]. Int J Oncol, 2017, 50(3):798-804. DOI: 10.3892/ijo.2017.3848.
[19] Svensson KJ, Christianson HC, Kucharzewska P, et al. Chondroitin sulfate expression predicts poor outcome in breast cancer[J]. Int J Oncol, 2011, 39(6):1421-1428. DOI: 10.3892/ijo.2011.1164.
[20] Xu Q, Lin W, Tao C, et al. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells[J]. Biochem Cell Biol, 2020, 98(3):362-369. DOI: 10.1139/bcb-2019- 0227.
[21] Sun W, Zhao F, Xu Y, et al. Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1[J]. Cell Death Dis, 2020, 11(7):496. DOI: 10.1038/s41419-020-2526-9.
[22] Lin X, Han T, Xia Q, et al. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1[J]. Cell Death Dis, 2021, 12(10):876. DOI: 10.1038/s41419-021- 04148-y.
[23] Cao C, Liu Y, Wang Q, et al. Expression of CHPF modulates cell proliferation and invasion in lung cancer[J]. Braz J Med Biol Res, 2020, 53(5):e9021. DOI: 10.1590/1414- 431x20209021.
[24] Schrijver WAME, Suijkerbuijk KPM, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2018, 110(6):568-580. DOI: 10.1093/jnci/djx273.
[25] Wu T, Dai Y. Tumor microenvironment and therapeutic response[J]. Cancer Lett, 2017, 387:61-68. DOI: 10.1016/j.canlet.2016.01.043.
[26] Reddy SM, Reuben A, Barua S, et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer[J]. Cancer Immunol Res, 2019, 7(6):1025-1035. DOI: 10.1158/2326-6066.CIR-18-0619.
[27] Liao WC, Yen HR, Chen CH, et al. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment[J]. Am J Cancer Res, 2021, 11(3):812-826.
[28] Ilieva KM, Cheung A, Mele S, et al. Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types[J]. Front Immunol, 2018, 8:1911. DOI: 10.3389/fimmu.2017. 01911.
[29] Mikami T, Kitagawa H. Biosynthesis and function of chondroitin sulfate[J]. Biochim Biophys Acta, 2013, 1830(10):4719-4733. DOI: 10.1016/j.bbagen.2013. 06.006.
[30] Fan YH, Xiao B, Lv SG, et al. Lentivirus‑mediated knockdown of chondroitin polymerizing factor inhibits glioma cell growth in vitro[J]. Oncol Rep, 2017, 38(2):1149-1155. DOI: 10.3892/or.2017.5731.
[31] Li Y, Gong H, Feng L, et al. Chondroitin polymerizing factor promotes breast carcinoma cell proliferation, invasion and migration and affects expression of epithelial-mesenchymal transition-related markers[J]. FEBS Open Bio, 2021, 11(2):423-434. DOI: 10.1002/2211-5463.13062.
[32] Chen X, Zhang Y, Shi Y, et al. MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2[J]. Int J Oncol, 2015, 47(4):1603-1611. DOI: 10.3892/ijo.2015.3143.
[33] Nieto MA. Context-specific roles of EMT programmes in cancer cell dissemination[J]. Nat Cell Biol, 2017, 19(5):416-418. DOI: 10.1038/ncb3520.
[34] Song R, Zhang J, Huang J, et al. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition[J]. Cancer Biomark, 2018, 22(3):565-573. DOI: 10.3233/CBM-181250.
|